Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Exploration of a Potential Amoxicillin MIC Threshold in Bismuth Quadruple Therapy for H. pylori Infection in Southeastern China.

Helicobacter·2026
Same author

CMOS-compatible Au doping boosts the hole carrier transport in the CVD-grown 2-inch monolayer WSe<sub>2</sub> films for p-type transistors.

Nanoscale·2026
Same author

Hybrid neural network for personnel recognition and tracking in remote bidding evaluation monitoring.

Scientific reports·2026
Same author

Enhancing Torque Output for a Magnetic Actuation System for Robotic Spinal Distraction.

Sensors (Basel, Switzerland)·2025
Same author

Growth of highly uniform 2-inch MoS<sub>2</sub> wafers using liquid precursor spraying.

Nanoscale·2025
Same author

Transformer-based multimodal precision intervention model for enhancing diaphragm function in elderly patients.

Frontiers in computational neuroscience·2025

相关实验视频

Updated: Jun 8, 2025

Author Spotlight: Generating Neuronal Phenotypic Profiles - A Protocol to Culture and Image Human Midbrain Dopaminergic Neurons
09:21

Author Spotlight: Generating Neuronal Phenotypic Profiles - A Protocol to Culture and Image Human Midbrain Dopaminergic Neurons

Published on: July 7, 2023

1.4K

多重机器学习识别了抑制NAFLD进展的关键基因PHLDA1

Zhenwei Yang1, Zhiqin Chen2,3, Jingchao Wang4

  • 1Department of Gastroenterology, The Fifth School of Clinical Medicine of Zhejiang, Huzhou Central Hospital, Chinese Medical University, No.1558, Sanhuan North Road, Wuxing District, Huzhou, Zhejiang Province, 313000, People's Republic of China. 2780779862@qq.com.

Inflammation
|November 4, 2024
PubMed
概括
此摘要是机器生成的。

普莱克斯特林类似域家族A成员1 (PHLDA1) 的同质性可能是非酒精性脂肪肝疾病 (NAFLD) 的新生物标志物. 过度表达PHLDA1减少脂质积累,这表明它在NAFLD治疗中的潜力.

关键词:
生物标志物生物标志物机器学习策略 机器学习策略这是NAFLD.在 PHLDA1 中.

更多相关视频

Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model
08:20

Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model

Published on: December 2, 2022

1.8K
In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

20.7K

相关实验视频

Last Updated: Jun 8, 2025

Author Spotlight: Generating Neuronal Phenotypic Profiles - A Protocol to Culture and Image Human Midbrain Dopaminergic Neurons
09:21

Author Spotlight: Generating Neuronal Phenotypic Profiles - A Protocol to Culture and Image Human Midbrain Dopaminergic Neurons

Published on: July 7, 2023

1.4K
Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model
08:20

Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model

Published on: December 2, 2022

1.8K
In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

20.7K

科学领域:

  • 肝病学和分子生物学
  • 生物标志物发现发现
  • 基因组学就是基因组学.

背景情况:

  • 非酒精性脂肪肝 (NAFLD) 是一个日益严重的全球健康问题,其进展机制尚未完全理解.
  • 目前NAFLD的分子标志物缺乏强有力的临床证据,需要识别新的生物标志物以改善预测,预防和个性化治疗.

研究的目的:

  • 通过生物信息学和机器学习方法,识别非酒精性脂肪性肝病 (NAFLD) 的新基因和潜在生物标志物.
  • 调查已识别的基因在NAFLD病原体中的作用及其与免疫细胞的关联.
  • 在NAFLD的细胞和动物模型中验证发现.

主要方法:

  • 下载并分析了基因表达综合 (GEO) 数据集,用于差异基因表达和功能丰富分析.
  • 使用权重基因共同表达网络分析 (WGCNA) 和机器学习算法来选关键基因.
  • 用于诊断价值评估的受体操作特征 (ROC) 分析和用于免疫细胞关联研究的CIBERSORT/scRNA-seq.
  • 在体外 (肝硬化细胞模型) 和体内 (老鼠NAFLD模型) 验证的结果.

主要成果:

  • 确定了23个重叠的差异表达基因 (DEGs),与亡和p53信号传递等途径相关.
  • 发现了像域家族A成员1 (PHLDA1) 这样的一种普莱克斯特林同质性作为关键基因,在NAFLD中降低调控,具有高诊断准确性.
  • PHLDA1与免疫细胞,特别是巨细胞有显著的相关性,其下调被证实在体外和体内.
  • 在肝硬化模型中,PHLDA1的过度表达减少了脂质积累和关键脂原基因表达 (FASN,SCD-1,CD36).

结论:

  • 在非酒精性脂肪性肝病 (NAFLD) 中,PHLDA1的下调,并显示出作为诊断生物标志物的潜力.
  • 通过抑制肝脏脂质生成和脂质积累,PHLDA1发挥着保护作用,这表明它是治疗点.
  • 对PHLDA1的进一步研究可能会导致用于NAFLD预测,诊断和有针对性的预防的新战略.